ClinicalTrials.gg
RecruitingNCT06240754Updated Nov 18, 2026

Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial

A Phase 2 interventional study of Enasidenib in Clonal Cytopenia of Undetermined Significance and CCUS Clonal Cytopenia of Undetermined Significance, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Washington University School of Medicine · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Nov 18, 2026Sponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Cytopenia with a site in United States — 17 open to participants now, 22 under way, 2 of them phase 3. Cytopenia · United States.

Planned enrollment
23rd of 32
15 · median 33
Started
2024
with 3 others
Phase 2
13 of 51
8 open now
Primary completion
2028-05
later than 8 of 20 live
Registered
42nd of 51
by date
Lead sponsor
2 of 51
Washington University School of Medicine

Among the 51 studies in Cytopenia with a site in United States, this one is the 23rd largest by planned enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2024, is one of 13 in phase 2, reaches primary completion later than 8 of the 20 other live ones, and was the 42nd registered.

Cytopenia

81 studies on the registry are indexed under Cytopenia; 25 are open to participants now.

Browse Cytopenia studies →

Open to participants now

17 of the 51 studies in Cytopenia with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Cytopenia studies recruiting now, 17 (85%) set no upper age limit and 1 (5%) stops at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Cytopenia with a site in United States, or all of them as a file.
02

Study summary

Study researchers think that a drug called enasidenib may help people with clonal cytopenia of undetermined significance (CCUS) because the drug blocks the mutated IDH2 protein, which may improve blood cell counts. The purpose of this study is to find out whether enasidenib is a safe and effective treatment for CCUS.

03

Conditions studied

  • Clonal Cytopenia of Undetermined Significance
  • CCUS Clonal Cytopenia of Undetermined Significance

Browse trials for

Keywords

  • Clonal Cytopenia of Undetermined Significance
  • CCUS
  • IDH2
  • Enasidenib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Unexplained cytopenia for at least 6 months. Cytopenia is defined as the presence of ≥1 blood count indexes below the following thresholds:

    • \<10 g/dL
    • ANC \<1.8 × 109/L
    • \<100 × 109/L
  • IDH2 gene mutation (R140 or R172), performed locally, at a frequency ≥ 2%.
  • At least 18 years of age.
  • performance status 0-2
  • Adequate organ function as defined below:

    • (SGOT)/ALT(SGPT) ≤ 3.0 x IULN
    • Serum total \< 1.5 x IULN (un upper limit of bilirubin 5 mg/dL is acceptable if it can be attributed to Gilbert's syndrome or erythropoiesis)
    • > 50 mL/min by Cockcroft-Gault estimation or serum creatinine ≤ 2 x IULN
  • The effects of enasidenib on the developing human fetus are unknown. For this reason, women of and men must agree to use adequate prior to study entry, for the duration of study participation, and for 24 months after the last dose of enasidenib. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of the study, and for 4 months after the last dose of enasidenib.
  • Ability to understand and willingness to sign an IRB approved written document. Legally authorized representatives may sign and give informed consent on behalf of study participants.

Exclusion criteria

Exclusion Criteria:

  • Indication of hematologic disease by bone marrow within 6 months of study entry.

    • Evidence of disease progression from time of bone marrow biopsy to enrollment based on investigator review of symptoms and complete blood counts
  • Active (defined as > 1 cm disease on most recent CT scan in the past 6 months).
  • Currently receiving therapy for solid tumor malignancy or received within the last 6 months.
  • Currently receiving any other agents.
  • Known dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to enasidenib or other agents used in the study.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
  • Pregnant and/or breastfeeding. Women of must have a negative pregnancy test within 72 hours of study entry.
  • Positive direct Coombs test.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Enasidenib

    Participants will receive enasidenib 100 mg daily for 18 cycles (each cycle is 28 days). Participants will continue treatment with enasidenib until confirmed progression to AML or MDS, development of unacceptable toxicity, or suspicion of disease progression, provided the patient is deriving clinical benefit, which will be determined at the discretion of the principal investigator.

    Drug: Enasidenib

Interventions

06

What researchers measure

Primary outcomes

  1. Best hematologic response

    Hematologic response to enasidenib will be evaluated according to a modified version of the IWG 2006 Criteria for Hematologic Improvement for patients with MDS on clinical trials

    Time frame: Up to 18 cycles (each cycle is 28 days) of treatment (up to approximately 17 months)

Secondary outcomes

  1. Toxicity as measured by the number of adverse events experienced by participant

    Measured by CTCAE v 5.0

    Time frame: From start of treatment through 30 days after the last day of treatment (up to approximately 18 months)

  2. Change in mutant IDH2 variant allele fraction

    The IDH2 variant allele fraction reflects the clonal dominance in the blood. Blood samples will be drawn at various time points throughout the study to determine the IDH2 variant allele fraction. The lower the IDH2 variant allele fraction the better the outcome.

    Time frame: Baseline, day 1 of cycles 3/6/9/12/15 (each cycle is 28 days), and end of treatment (up to approximately 17 months)

  3. Duration of hematologic improvement

    Time frame: From start of treatment through completion of treatment (estimated to be 17 months)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article after deidentification (including text, tables, figures and appendices) will be available.

Supporting information: Study protocol, Statistical analysis plan

Time frame: The data will be available immediately following publication with no end date.

Access criteria: The data will be available immediately following publication with no end date. Access will be provided to anyone and for any purpose.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for May 2028, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2024
First posted
Feb 5, 2024
StartActual
Oct 10, 2024
Primary completionEst.
May 31, 2028
CompletionEst.
Jun 30, 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sponsor
Collaborators added: Gateway for Cancer Research
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Sponsor Collaborators added: Gateway for Cancer Research
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06240754
Collaborators
Bristol-Myers Squibb, Damon Runyon Cancer Research Foundation, Gateway for Cancer Research
Responsible party
Sponsor
First posted
Feb 5, 2024
Start date
Oct 10, 2024
Primary completion
May 31, 2028 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Giulia Petrone, M.D.
Contact
gpetrone@wustl.edu
314-362-6826
Giulia Petrone, M.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enasidenib

Start the discussion